Search

Displaying results 3901 - 3910 of 5504 in total
  1. Drug

    Lutetium Lu 177 dotatate

    go.drugbank.com/drugs/DB13985
    ApprovedInvestigational

    It is a first radiopharmaceutical agent to be approved for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and is indicated for adult patients with somatostatin receptor-positive GEP-NETs [L1191 … In a clinical trial involving patients with advanced somatostatin receptor-positive GEP-NET, the treatment of Lutetium Lu 177 dotatate in combination with octreotide resulted in longer progression-free

  2. Drug

    3-hydroxyanthranilic acid

    go.drugbank.com/drugs/DB03644
    Experimental

    It may be a free radical scavenger and a carcinogen.

  3. Drug

    Zeatin

    go.drugbank.com/drugs/DB11337
    Investigational

    (Grant & Hackh's Chemical Dict, 5th ed)

    Synonyms: (E)-2-methyl-4-(1H-purin-6-ylamino)but-2-en-1-ol, (E)-zeatin
  4. Drug

    KF-0210

    go.drugbank.com/drugs/DB17476
    Investigational

    It is being investigated for cancers.

  5. Drug

    Sasanlimab

    go.drugbank.com/drugs/DB18849
    Investigational

    Sasanlimab is under investigation in clinical trial NCT06218069 (Immuno-pet Imaging Responses Administered Immune Checkpoint Inhibitor).

  6. Drug

    Apararenone

    go.drugbank.com/drugs/DB15024
    Investigational

    Apararenone is under investigation in clinical trial NCT02531568 (Drug Interaction Study of Warfarin and MT-3995).

  7. Drug

    Cusatuzumab

    go.drugbank.com/drugs/DB15100
    Investigational

    [A241045] It is currently being investigated in the Phase 2 CULMINATE trial, in combination with [azacitidine], for the treatment of newly-diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic

  8. Drug

    Renzapride

    go.drugbank.com/drugs/DB04917
    Investigational

    It has been suggested that renzapride is effective in the treatment of irritable bowel syndrome with alternating stool pattern. It is being developed by Alizyme of the UK.

  9. Drug

    EA-2353

    go.drugbank.com/drugs/DB18506
    Investigational

    EA-2353 is a small molecule inhibitor of kinase mediators of the Wnt pathway.

  10. Drug

    Methyl-D9-choline

    go.drugbank.com/drugs/DB12628
    Investigational

    Methyl-D9-choline is under investigation in clinical trial NCT01807910 (ER Stress in NAFLD).